A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
Marcy E YonkerJennifer Williams McVigeLeonid ZeitlinHester VisserPublished in: Headache (2022)
The effect of high-dose ZNS on the primary endpoint of pain-free status at 2 h did not achieve statistical significance. ZNS was safe and well tolerated in this pediatric population.
Keyphrases
- double blind
- placebo controlled
- phase iii
- phase ii
- clinical trial
- study protocol
- high dose
- quantum dots
- end stage renal disease
- phase ii study
- open label
- newly diagnosed
- ejection fraction
- chronic pain
- chronic kidney disease
- liver failure
- prognostic factors
- low dose
- squamous cell carcinoma
- randomized controlled trial
- peritoneal dialysis
- patient reported outcomes
- neuropathic pain
- spinal cord
- locally advanced
- drug induced
- intensive care unit